Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines

Area of Science:

• Oncology
• Hematology
• Clinical Practice Guidelines

Background:

• The National Comprehensive Cancer Network (NCCN) Guidelines provide clinical management recommendations for Hodgkin Lymphoma (HL).
• Previous guidelines (2012) did not recommend interim PET scans for favorable stage I-II HL.
• Lymphocyte-predominant HL (LPHL) management has evolved.

Purpose of the Study:

• To update the NCCN Clinical Practice Guidelines for Hodgkin Lymphoma based on recent evidence.
• To refine recommendations for interim restaging in early-stage favorable HL.
• To incorporate new treatment options for LPHL and relapsed/progressive HL.

Main Methods:

• Reevaluation of evidence regarding interim PET imaging in HL.
• Inclusion of new therapeutic agents and strategies.
• Revision of clinical management pathways for classical HL and LPHL.

Main Results:

• Diagnostic CT scans are now recommended for interim restaging after chemotherapy in favorable stage I-II HL.
• Maintenance rituximab for two years is an option for first-line treated LPHL (stage IB-IIB or III-IV).
• Brentuximab vedotin is an option for patients with relapsed or progressive disease post-second-line therapy or stem cell rescue.

Conclusions:

• Updated NCCN Guidelines reflect significant changes in HL management.
• CT scan is preferred for interim restaging in specific early-stage HL cases.
• New treatment options enhance therapeutic strategies for LPHL and relapsed/refractory HL.